Impact of pre-implant lower urinary tract symptoms on postoperative urinary morbidity after permanent prostate brachytherapy.
Impact of pre-implant lower urinary tract symptoms on postoperative urinary morbidity after permanent prostate brachytherapy.
复制标题
植入前下尿路症状对永久性前列腺近距离放射治疗术后尿路发病率的影响。
DOI：
10.1111/j.1442-2042.2012.03105.x
复制
发表时间：
2012
期刊：
影响因子：
--
通讯作者：
Matsubara A.
中科院分区：
文献类型：
--
作者：
Teishima J;Iwamoto H;Miyamoto K;Shoji K;Masumoto H;Inoue S;Kobayashi K;Kajiwara M;Matsubara A.
目的：评估基线下尿路症状对接受 125-I 永久性前列腺近距离放射治疗的前列腺癌患者术后泌尿系统发病率的影响。方法：共有 104 名前列腺癌患者纳入本研究。在永久性前列腺近距离放射治疗后，使用国际前列腺症状评分和扩展前列腺癌综合指数对他们的尿路发病率进行 12 个月或更长时间的随访。根据基线国际前列腺症状评分将患者分为两组：国际前列腺症状评分低组（评分≤7）和国际前列腺症状评分高组（评分≥8）。根据永久性前列腺近距离放射治疗前以及所有放射治疗结束后 1、3、6、9 和 12 个月测量的国际前列腺症状评分和扩展前列腺癌指数综合结果，估计每组的泌尿发病率。结果：总体平均总国际前列腺症状评分、国际前列腺症状评分生活质量评分和扩展前列腺癌指数综合泌尿相关评分显着高于对照组。治疗结束后1个月时病情加重，但治疗后逐渐改善，12个月内恢复至基线水平。即使在高国际前列腺症状评分组中，永久性前列腺近距离放射治疗后1-3个月时，国际前列腺症状评分和国际前列腺症状评分生活质量评分也显着恶化，然后恢复到基线水平，且没有延长。尽管与低国际前列腺症状评分组相比，高国际前列腺症状评分组的排尿相关扩展前列腺癌指数综合评分在永久性前列腺近距离放射治疗后1个月时明显较差，但已恢复至基线水平，且没有延长。结论：目前的研究结果表明，植入前存在下尿路症状并不会延长永久性前列腺近距离放射治疗后的泌尿系统发病率。
Objectives:To assess the impact of baseline lower urinary tract symptoms on postoperative urinary morbidity in patients being treated for prostate cancer with 125‐I permanent prostate brachytherapy.Methods:A total of 104 prostate cancer patients were enrolled in this study. Their urinary morbidity was followed up using the International Prostate Symptom Score and Expanded Prostate Cancer Index Composite for 12 months or more after permanent prostate brachytherapy. Patients were classified into two groups based on their baseline International Prostate Symptom Score: the low International Prostate Symptom Score group (score ≤ 7) and the high International Prostate Symptom Score group (score ≥ 8). Urinary morbidity was estimated in each group based on the results of the International Prostate Symptom Score and Expanded Prostate Cancer Index Composite measured before permanent prostate brachytherapy, and at 1, 3, 6, 9 and 12 months after the end of all radiation therapy.Results:The overall mean total International Prostate Symptom Score, International Prostate Symptom Score quality of life score, and urinary‐related scores for Expanded Prostate Cancer Index Composite were significantly worse at 1 month after the end of treatment, but they improved gradually after the treatment and recovered to the baseline level within 12 months. Even in the high‐International Prostate Symptom Score group, the International Prostate Symptom Score and International Prostate Symptom Score Quality of Life score were significantly worse at 1–3 months after permanent prostate brachytherapy, and then recovered to the baseline level without prolongation. Although the urination‐related Expanded Prostate Cancer Index Composite score in the high‐International Prostate Symptom Score group was significantly worse at 1 month after permanent prostate brachytherapy in comparison with that in the low‐International Prostate Symptom Score group, it recovered to the baseline level without prolongation.Conclusions:The present findings suggest that the presence of lower urinary tract symptoms before implantation does not prolong urinary morbidity after permanent prostate brachytherapy.